New FDA hiring data show the agency’s drug and biologics centers recorded nearly 1,000 net departures in the last quarter of fiscal 2025, marking a historic outflow that offsets hundreds of hires. The staffing losses raise capacity concerns for review timelines, inspections and policy implementation at a time of high regulatory workload and accelerating therapeutic innovation. Industry stakeholders and policy observers flagged potential impacts on approval cycles and post‑market surveillance. The data underline broader workforce challenges facing regulators and the need for strategic retention efforts.